LeMaitre Vascular, Inc. (NASDAQ:LMAT) Receives $97.60 Average Target Price from Analysts

Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) have been given an average recommendation of “Hold” by the five brokerages that are presently covering the stock, Marketbeat reports. Three equities research analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 1 year price target among analysts that have covered the stock in the last year is $97.60.

A number of equities research analysts have recently weighed in on the company. Barrington Research upgraded LeMaitre Vascular from a “market perform” rating to an “outperform” rating and set a $95.00 target price for the company in a research report on Wednesday, August 6th. Cantor Fitzgerald lifted their price objective on LeMaitre Vascular from $92.00 to $95.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 6th.

Insider Buying and Selling

In other news, CEO George W. Lemaitre sold 100,000 shares of the company’s stock in a transaction dated Wednesday, August 6th. The stock was sold at an average price of $93.51, for a total value of $9,351,000.00. Following the completion of the sale, the chief executive officer directly owned 1,727,003 shares of the company’s stock, valued at $161,492,050.53. This represents a 5.47% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director David B. Roberts sold 10,815 shares of the company’s stock in a transaction dated Monday, August 11th. The shares were sold at an average price of $92.39, for a total value of $999,197.85. Following the completion of the sale, the director directly owned 17,976 shares of the company’s stock, valued at approximately $1,660,802.64. This trade represents a 37.56% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 120,815 shares of company stock valued at $11,280,206. Insiders own 9.50% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in LMAT. First Trust Advisors LP lifted its holdings in LeMaitre Vascular by 52.7% during the second quarter. First Trust Advisors LP now owns 612,028 shares of the medical instruments supplier’s stock worth $50,829,000 after acquiring an additional 211,280 shares in the last quarter. Annex Advisory Services LLC lifted its holdings in LeMaitre Vascular by 535.2% during the second quarter. Annex Advisory Services LLC now owns 219,667 shares of the medical instruments supplier’s stock worth $18,243,000 after acquiring an additional 185,085 shares in the last quarter. Millennium Management LLC raised its stake in shares of LeMaitre Vascular by 119.8% in the 1st quarter. Millennium Management LLC now owns 211,222 shares of the medical instruments supplier’s stock valued at $17,722,000 after purchasing an additional 115,141 shares during the period. Grandeur Peak Global Advisors LLC acquired a new stake in shares of LeMaitre Vascular in the 2nd quarter valued at about $6,275,000. Finally, Invesco Ltd. raised its stake in shares of LeMaitre Vascular by 34.5% in the 1st quarter. Invesco Ltd. now owns 235,436 shares of the medical instruments supplier’s stock valued at $19,753,000 after purchasing an additional 60,438 shares during the period. 84.64% of the stock is currently owned by institutional investors.

LeMaitre Vascular Trading Down 2.1%

LMAT stock opened at $92.29 on Wednesday. The company has a market cap of $2.09 billion, a P/E ratio of 44.80, a PEG ratio of 2.42 and a beta of 0.79. LeMaitre Vascular has a twelve month low of $71.42 and a twelve month high of $109.58. The company has a quick ratio of 11.74, a current ratio of 13.96 and a debt-to-equity ratio of 0.46. The business has a fifty day moving average of $89.69 and a 200-day moving average of $86.06.

LeMaitre Vascular (NASDAQ:LMAT) last released its earnings results on Tuesday, August 5th. The medical instruments supplier reported $0.60 earnings per share for the quarter, topping analysts’ consensus estimates of $0.57 by $0.03. The company had revenue of $63.15 million during the quarter, compared to the consensus estimate of $62.48 million. LeMaitre Vascular had a return on equity of 13.67% and a net margin of 20.08%.The firm’s quarterly revenue was up 15.0% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.52 earnings per share. LeMaitre Vascular has set its Q3 2025 guidance at 0.540-0.590 EPS. FY 2025 guidance at 2.230-2.370 EPS. As a group, equities research analysts expect that LeMaitre Vascular will post 1.94 EPS for the current year.

LeMaitre Vascular Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, September 4th. Stockholders of record on Thursday, August 21st were paid a $0.20 dividend. The ex-dividend date of this dividend was Thursday, August 21st. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.9%. LeMaitre Vascular’s dividend payout ratio is 38.83%.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.